From: Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities
Fungi-derived compounds | Functions | References | |
---|---|---|---|
Quorum-sensing molecules | Farnesol | Filamentous growth and formation ↓ C. albicans biofilm formation ↓ | |
Drug-resistance ↓ Synergy with fluconazole, amphotericin B or micafungin, anti-fungal AMP peptidomimetics, chitosan (CS), and cysteine protease metacaspase | |||
Tyrosol | C. albicans biofilm formation ↓ | ||
Fungal secondary metabolites | Source of antibiotics and immunosuppressant drugs Hepatotoxicity and/or nephrotoxicity | ||
Fungi-derived extractives | (1,3)/(1,6)-β-glucan | Obesity property ↓ | |
Pyronepolyene C-glucoside iso-D8646-2-6 | Influenza A virus (H1N1) infection ↓ | ||
Xanthones | Virus infection (H1N1, simplex virus types 1 and 2) ↓ | ||
Some mangrove-associated or soil-associated fungus-derived compounds | Virus infection ↓ | ||
Other compounds | Candidalysin | Systematic infection ↑ Phagocytic clearance ↓ Severity of ethanol-associated hepatitis ↑ | |
Prostaglandins E2 (PGE2) | Biofilm formation ↑ Yeast to hyphae transition ↑ C. albicans clearance by phagocytes ↓ | ||
Oxylipins | Modulating immune responses |